A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority of patients who initiated CT-P13 switched from the reference product (Remicade) or another biologic or targeted synthetic disease-modifying antirheumatic drug.
A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority of patients who initiated CT-P13 switched from the reference product or another biologic or targeted synthetic disease-modifying antirheumatic drug (tsDMARD).
They observed disease activity “remained stable” in patients who switched from the reference product or another infliximab biosimilar and improved in patients switching from a non-infliximab biologic or tsDMARD and in biologic/tsDMARD-naive patients. The study used data from CorEvitas RA Registry, a large, observational clinical registry including data collected from patients and their rheumatologists at routine visits.
The anti-tumor necrosis factor (TNF)-α infliximab is approved for use in several inflammatory diseases including RA. According to the authors, randomized controlled trials have established “comparable clinical outcomes” in CT-P13 and the reference product. However, they said, “better characterization” of real-world patients with RA beginning treatment with CT-P13 and switching from the reference product, “is warranted to confirm that clinical trial data may be extrapolated to the real-world setting.”
Patients with RA in the CorEvitas RA Registry treated with CT-P13 who had Clinical Disease Activity Index (CDAI) data recorded at baseline and 6 months were included in the study. Of 318 patients who initiated CT-P13, 176 had CDAI scores recorded at baseline and 6 months. Of these, 73 (41%) switched from the reference product, 61 (35%) switched from another biologic or tsDMARD, 32 (18%) were biologic-naive, and 10 (6%) switched from another infliximab biosimilar. The authors noted patients who had switched from the reference product had a longer disease duration than biologic-naive patients at baseline.
The primary outcome of the study was the proportion of patients with moderate or high disease activity (CDAI > 10) at baseline achieving low disease activity (CDAI ≤ 10) at 6 months. Secondary outcomes included change in CDAI from baseline to 6 months, proportion of patients achieving remission (CDAI ≤ 2.8) at 6 months, and patient-reported outcomes (PROs) of pain and fatigue.
At 6 months, 119 (68%) patients remained on CT-P13 therapy, 35 (20%) discontinued the biosimilar and did not start another biologic, and 22 (12.5%) switched to another biologic.
In patients switching from the reference product or other infliximab biosimilars to CT-P13, the changes in clinical outcomes were “small,” the authors said. In these patients, a not statistically significant increase in CDAI was observed, as well as a “small numerical increase” patient global assessment (PGA) score of 2.1 (SD, 18.1; 95% CI, –1.8 to 6.0). There were improvements in CDAI in patients switching from another biologic or tsDMARD (–4.7; SD, 11.9; 95% CI, –7.6 to –1.7) and in biologic/tsDMARD-naive patients (–4.1; SD, 10.9; 95% CI, –7.8 to –0.3). PGA scores decreased by 3.6 (SD, 25.9; 95% CI, –10.2 to 2.9) in those switching from non-infliximab biologics or tsDMARDs and by 4.1 (SD, 23.4; 95% CI, –12.2 to 4.0) in patients naive to biologics and tsDMARDs. Changes in PROs were “generally small” in all patients, according to the investigators.
In patients with moderate or high disease activity at baseline, 32.9% (95% CI, 22.9-42.9) achieved low disease activity at 6 months. Among groups of patients, the greatest proportion achieving low disease activity was in those who had switched to CT-P13 from another biologic (38%), compared to those who switched from the reference product or another biosimilar (26%), and biologic/tsDMARD-naïve patients (29%).
The lowest rate of remission was observed in patients who had switched from a non-infliximab biologic or tsDMARD (7.4%), compared to patients who had switched from the reference product or another infliximab biosimilar (18%) and those who were naive to biologics or tsDMARDs (19%). The authors commented that the greater response they observed in the treatment-naive and switching from non-infliximab treatment groups than the group switching from the reference product or other infliximab biosimilars was expected, “since changing from the originator product or other biosimilar product should effectively represent a continuation of therapy.”
The investigators said their findings “provide insights for clinicians regarding expected disease effectiveness outcomes following switching” to CT-P13 in RA, which could “potentially alleviate hesitation in its use.” To their knowledge, this is the first real-world study of CT-P13 initiation in US patients with RA, and they said their findings suggest real-world outcomes at 6 months of CT-P13 treatment “are comparable with efficacy outcomes in clinical trials.”
Reference
Baker JF, Bakewell C, Dikranian A, et al. Characteristics and 6-month outcomes in patients with rheumatoid arthritis initiating infliximab biosimilar IFX-dyyb in a real-world setting. Rheumatol Ther. 2024;11(3):841-853. doi:10.1007/s40744-024-00653-6
Treatment Persistence, Safety After Switching to Infliximab Biosimilars in Canadians With IBD
October 5th 2024A retrospective study of a mandatory nonmedical switch in Canada found no significant differences in rates of treatment persistence, loss of response, or adverse events in patients with inflammatory bowel disease (IBD) on maintenance therapy 1 year post-switch.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Patient-Reported Outcomes Similar Between Adalimumab-adbm, Reference Product in VOLTAIRE-RA Study
September 28th 2024A summary of research written by Vibeke Strand, MD, clinical professor in division of immunology/rheumatology at Stanford University School of Medicine, gave an overview of patient-reported outcomes (PROs) in the VOLTAIRE-RA trial.
Eye on Pharma: EC Approved Ustekinumab; Zymfentra Expansion; Biosimilar Policy Briefing
September 26th 2024The European Commission (EC) approved Celltrion's ustekinumab biosimilar for chronic inflammatory diseases, Celltrion expanded access to Zymfentra (subcutaneous infliximab-dyyb) through partnerships with Cigna and Express Scripts, and the Association for Accessible Medicines held a policy briefing addressing barriers to biosimilar adoption.